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Abstract
HECT E3 ubiquitin ligases selectively recognize, bind, and ubiquitylate their 
substrate proteins to target them for 26S proteasomal degradation. There is increas-
ing evidence that HECT E3 ubiquitin ligase dysfunction due to misfolding and/or 
the gene encoding the protein being mutated is responsible for the development of 
different diseases. Apart from the more prominent and well-characterized E6AP 
and members of the NEDD4 family, new studies have begun to reveal how other 
members of the HECT E3 ubiquitin ligase family function as well as their links 
to disease and developmental disorders. This chapter provides a comprehensive 
discussion on the more mysterious members of the HECT E3 ubiquitin ligase 
family and how they control intracellular processes. Specifically, AREL1, HACE1, 
HECTD1, HECTD4, G2E3, and TRIP12 will be examined as these enzymes have 
recently been identified as contributors to disease development.
Keywords: apoptosis, AREL1, cancer, HECT E3 ubiquitin ligase, G2E3, HACE1, 
HECT, HECTD1, HECTD4, neurodevelopment, proteasomal degradation, TRIP12, 
ubiquitin, ubiquitylation
1. Introduction
1.1 HECT E3 ubiquitin ligase-dependent ubiquitylation
Ubiquitylation is an essential post-translational modification that regulates 
numerous intracellular processes including protein localization and trafficking, 
DNA damage response, immune system and viral response, apoptosis and prote-
olysis [1, 2]. E3 ubiquitin ligases play an important role in recognizing, binding, 
and covalently attaching ubiquitin to their various substrates to elicit a specific 
cellular response [3]. The homologous to E6AP C-terminus (HECT) E3 ubiquitin 
ligases are a unique subfamily that use a multistep pathway to selectively target 
substrate proteins for ubiquitylation [4]. HECT-dependent ubiquitylation requires 
the recruitment of an E2 ubiquitin conjugating enzyme charged with ubiquitin to 
the N-terminal lobe of the HECT domain on the E3 ligase [5, 6]. The ubiquitin cargo 
is then transferred from the E2 enzyme to the conserved catalytic cysteine within 
the C-terminal lobe of the HECT domain via a transthiolation reaction to form a 
thioester bond. The HECT E3~ubiquitin complex will then bind to a substrate and 
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covalently attach ubiquitin on to a lysine residue of the substrate protein forming 
a stable isopeptide bond between the C-terminus of ubiquitin and the ε-amine of 
the substrate lysine [3, 5, 6]. This process can be repeated numerous times to form 
different polyubiquitin chain linkages with the specific HECT E3 ubiquitin ligase 
dictating the type(s) of ubiquitin linkages that are built [2, 7].
Chain types Linker Proposed function
Monoubiquitylation
Monoubiquitylation/
multi-monoubiquitylation
Endocytosis [9]
DNA damage repair [10–15]
Histone regulation [10–15]
Mitophagy [10–15]
Protein localization [10–15]
Protein interactions [10–15]
Protein transportation [10–15]
Transcription activation [10–15]
Polyubiquitylation
Chain (homotypic) M1 Innate immunity [2, 9, 16]
Linear chain formation [9]
NF-κB activation [9, 16]
Signaling cascades [9, 16]
K6 DNA damage response [14]
NF-κB regulation [14]
Mitophagy [14]
K11 Cell cycle regulation [17]
DNA damage response [18]
Mitophagy [17]
NF-κB activation [16]
Protein degradation [17]
K27 DNA damage response [18]
Kinase activation [19]
Protein degradation [20]
Protein scaffolding [21]
Protein trafficking [22]
K29 DNA damage response [18]
Kinase activation [19]
Protein degradation [9]
K33 DNA damage response [10–15, 18]
Kinase activation [23]
Post-golgi trafficking [24]
T-cell signaling [23]
K48 Protein degradation [1, 2, 25]
K63 DNA damage response [9, 18]
NF-κB activation [9, 16]
Protein trafficking [9]
Chain (heterotypic; branched) M1/K63 NF-κB activation [16]
K11/K48 Protein degradation [26, 27]
K29/K48 Protein degradation [26]
K48/K63 Protein degradation [26]
K11/K63 Endocytosis [28]
Table 1. 
Ubiquitin conjugation determines the intracellular fate of a substrate protein.
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1.2  Ubiquitin attachment site(s) and chain type linkages determine the fate  
of a substrate protein
The destiny of a ubiquitin-tagged protein is dependent on (i) the site(s) of ubiqui-
tin attachment on the substrate, (ii) the number of ubiquitin moieties attached to the 
substrate (i.e. mono-, multi-mono-, or polyubiquitin), and (iii) the specific type(s) 
of linkages between the different ubiquitin molecules in a polyubiquitin chain (i.e. 
K48, K63, branched, etc.) [1, 2, 7]. Potential fates of a ubiquitin-tagged substrate 
include changes in cellular localization/trafficking, enhanced/inhibited protein activ-
ity, changes in protein–protein affinity/interactions, and proteolysis [1, 2, 6–8].
Differences in ubiquitin lysine linkage specificity determine the destination and/
or fate of the targeted protein in the cell (Table 1). For example, the well-estab-
lished K48-polyubiquitylation chain, heterotypic K11/K48-polyubiquitin, K29/
K48-polyubiquitin monoubiquitin tagged peptides and multiple monoubiquitin 
tagged proteins have also been found to signal for 26S proteasomal degradation [7, 8]. 
K63-polyubiquitin chains signal for protein degradation through the initiation of 
K48/K63 polyubiquitin branch formation [5] but cannot be recognized by the 26S 
proteosome [26]. To date, many different varieties of ubiquitin chain types have 
been identified, but their distinct biological functions remain unclear.
Monoubiquitylation can occur at one site or at multiple sites (multi- 
monoubiquitylation) on a substrate. Polyubiquitylation can build off of a mono-
ubiquitin attachment site with a specific lysine linkage (homotypic) or have multiple 
chains with different lysine linkages (branch) at the end of a growing ubiquitin 
chain (heterotypic). These modifications can also influence signaling pathways, 
whether it is through enhancing or inhibiting participating proteins and processes.
2.  The “other” HECT E3 ubiquitin ligases: important players in disease, 
yet poorly understood
The HECT E3 ubiquitin ligases can be categorized into three subfamilies –
NEDD4, HERC, and “other” – based on their sequence/structure similarity and 
domain architecture [4, 5]. Of the 28 HECT E3 ubiquitin ligases identified in 
humans, there are 12 “other” HECT E3 ubiquitin ligases that do not fall under the 
well-studied NEDD4 or HERC subfamilies. Each member of the “other” HECTs 
have variable N-terminal domains that are thought to be involved in protein–protein 
interactions and/or intracellular localization [4, 5]. Having prominent responsibili-
ties in cellular homeostasis would leave the impression there is ample research on the 
HECT E3 ubiquitin ligase family as a whole, however, there remain many unan-
swered questions about the biological functions and mechanisms of this important 
E3 ligase family, particularly for members of the more mysterious “other” subfamily. 
With new research and discoveries becoming available, there is mounting evidence 
that the lesser known HECT E3 ubiquitin ligases play critical roles in regulating 
intracellular processes and their dysfunction have been suggested to contribute 
to the onset of many diseases and disorders [4, 29–32]. Here we discuss the latest 
discoveries on these lesser known members of the HECT E3 ubiquitin ligases and on 
their emerging roles in developmental and neurological abnormalities, cancers, and 
embryogenesis.
2.1 AREL1, a key regulator of apoptosis and potential oncogenic drug target
Apoptosis resistant E3 ubiquitin protein ligase 1(AREL1; 823 residues) is a 
cytosolic enzyme responsible for regulating apoptosis through the inhibition of 
Ubiquitin - Proteasome Pathway
4
proapoptotic proteins via ubiquitylation [33]. AREL1 contains two immunoglobin-like 
folds (IGF) near its N-terminus that potentially mediate substrate binding and recog-
nition (Figure 1) [35, 36]. IGF domains assemble into a sandwich-like form consisting 
of antiparallel β-strands that allow for protein–protein interactions [36, 37].
Apoptosis (aka programmed cell death) is an important and highly regulated 
biological process that occurs during early embryonic development and the immune 
response [38, 39]. Once apoptosis is initiated the cell is committed to die, which is 
mediated by a caspase cascade [40]. Intrinsic apoptosis is turned on by the release 
of intermembrane mitochondrial proteins when cells are under oxidative stress 
[38, 39, 41]. In contrast, the extrinsic apoptotic pathway is activated by extracel-
lular signaling at the cell membrane leading to the formation of the death-inducing 
signaling complex (DISC) [42–44].
AREL1 was first identified in 2013 and was immediately recognized as an 
oncogenic target due to its inhibitory role in apoptosis [33]. Identified substrates 
for AREL1 include second mitochondrial activator of caspase (SMAC), HtrA serine 
peptidase 2 (HtrA2) and septin 4 (ARTS), which are known antagonists of inhibi-
tor of apoptosis proteins (IAPs) [45]. Studies have shown that AREL1 can build 
K48 and K63 polyubiquitin chains to target substrates for proteolysis, as well as 
atypical K33 polyubiquitin chains whose biological function is still being clarified 
[35, 46]. Various IAPs, including SMAC, HtrA1, and ARTS, are released from the 
mitochondrial intermembrane into the cytosol when the cell is triggered or stressed. 
AREL1 inhibits apoptosis by ubiquitylating these IAP antagonists with K48-linked 
polyubiquitin chains targeting the IAPs for proteasomal degradation [33].
The induction of apoptosis is thought to require the release of numerous IAPs 
in the cytosol to allow different signaling pathways to initiate apoptosis depending 
on the cell’s specific stress. For example, the release of SMAC into the cytosol allows 
it to bind cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), which then targets 
cIAP1/2 for proteasomal degradation to initiate apoptosis. However, when AREL1 
is present, SMAC is ubiquitylated by AREL1 and degraded, thus blocking SMAC-
cIAP1/2 complex formation enabling cell survival [33]. Many cancer therapies are 
interested in specifically turning on apoptosis through IAPs in cancer cells [47–49], 
Figure 1. 
AREL1 domain architecture. AREL1 contains a putative immunoglobulin fold domain (IGF, residues 52-158) 
and the canonical HECT domain (436-823) as annotated on UniProt and InterPro. Representative crystal 
structures of an IGF fold (human IGF FAB in yellow/orange; PDB 7FAB [34]), which is suggested to mediate 
AREL1 substrate binding and recognition, while the AREL1 HECT domain (HECTN−lobe in green, HECTC−lobe 
in blue, catalytic cysteine C790 in red; PDB 6JX5 [35]) is required for ubiquitylation activity. Structures were 
visualized using PyMol.
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thus AREL1 could prove to be a novel enzyme in drug development. Continued 
studies on AREL1’s mechanisms in controlling cell death are warranted.
2.2 HACE1, a prominent tumor suppressor with dual function
First identified in 2004, HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 (HACE1; 909 residues) has been shown to take part in 
various cellular processes. For example, HACE1 is best known as a tumor sup-
pressor as altered HACE1 expression levels have been observed in various cancers 
including colorectal, breast, liver, kidney, osteosarcoma, lymphoma and gastric 
cancer [50–54]. HACE1 contains six ankyrin repeats near its N-terminus that 
likely take part in HACE1-substrate recognition and protein–protein interactions 
(Figure 2). While it is not yet fully understood how the ankyrin repeats support 
HACE1 function, ankyrin repeats in other proteins have been shown to instigate the 
development of a wide array of diseases including cancer [56]. HACE1 also supports 
Golgi membrane biogenesis during cell division by ubiquitylating members of the 
Ras-related superfamily of small G proteins [57].
Studies have shown that HACE1 expression levels are altered when comparing 
normal and cancerous tissue. Specifically, in the Wilms’ tumor cell line, HACE1 
expression was essentially nonexistent, whereas in other cancer cell lines expression 
levels were lower than average [50]. This study concluded that HACE1 was essential 
in repressing cancer development as the lowered expression levels of HACE1 were 
not mutation dependent. Low expression levels of HACE1 have also been observed in 
other cancer cell lines. For instance, it was found that the methylation of the HACE1 
promoter resulted in decreased HACE1 expression in liver cancer cells, which in turn 
decreased HACE1’s ability to ubiquitylate its identified substrates optineurin (OPTN) 
and microtubule-associated proteins 1A/1B light chain 3B protein [53]. Many differ-
ent substrates of HACE1 have been identified to date (summarized in [4]), including 
β2-adrenergic receptor (ß2AR) [58], OPTN [59], retinoic acid receptor beta (RAR-β)  
[57], tumor necrosis factor receptor-2 (TNFR2) [60], and various Ras-related 
Figure 2. 
Predicted domain architecture of HACE1. HACE1 contains six putative ankyrin-repeats (ANK; residues 
64-258) and a HECT domain (574-909) as annotated on UniProt and InterPro. Representative crystal 
structures of an ANK repeat fold (in shades of pink, PDB 4O60 [55]), which is likely involved in HACE1 
substrate binding and recognition, and a HECT domain (HECTN-lobe in green, HECTC-lobe in blue; PDB 
6JX5 [35]) found at HACE1’s C-terminus that is required of ubiquitylation activity. Structures were visualized 
using PyMol.
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proteins [57, 58, 61–65]. Expanded studies on how HACE1 binds and recognizes its 
substrates are needed to further clarify the role of HACE1 in cancer development.
HACE1 also plays an essential role in neurodevelopment as it was recently 
shown to be involved in the spastic paraplegia and psychomotor retardation with or 
without seizures (SPPRS) phenotype [66]. HACE1 also has cardiac protection func-
tion during hemodynamic stress when it was shown in mice with HACE1 deficiency, 
their susceptibility to accelerated heart failure greatly increased [67]. This suggests 
that HACE1 has a critical role in protecting the heart from various stresses, thus 
making it a potential cardiac drug target.
2.3 HECTD1, an important regulator in neurodevelopment
HECT domain containing E3 ubiquitin protein ligase 1 (HECTD1; 2610 residues) 
was discovered in 2007 as a novel and important regulator of neurodevelopment 
[68]. HECTD1 has similar domain architecture to HACE1 with four ankyrin repeats 
near its N-terminus and a C-terminal HECT domain (Figure 3). HECTD1 plays 
an important role in pulmonary fibrosis during endothelial-mesenchymal transi-
tion (EndMT) with reports of increased circular RNA HECTD1 (circHECTD1) 
transcription, which causes decreased HECTD1 protein expression in lung tissue 
[72, 73]. Elevated circHECTD1 gene expression has also been found in patients with 
acute ischemic stroke (AIS) [74]. HECTD1 also contains a Smad4 activation SAD1/
UNC (SUN) domain and a mind bomb (MIB) domain, with each having unique 
roles in intracellular signaling due to Smad-DNA complex formation and cellular 
interactions through the Notch pathway, respectively [75, 76].
HECTD1 supports fetal growth and proper placenta development. Specifically, 
HECTD1 aids in the development of the labyrinthine and junctional zones of the 
placenta, regions where the fetus acquires nutrients and disposes of waste, as well as 
a bilayer between the labyrinthine and decidual cells, respectively [77, 78]. HECTD1 
ensures the proper size development of the labyrinthine, yet the mechanisms to ensure 
this are still not fully understood. Mutations within HECTD1 lead to the onset of irreg-
ular labyrinthine development, which in turn depletes nutrients for the fetus. Fetal 
fatality can occur without proper maintenance of these placental regions, suggesting 
Figure 3. 
HECTD1 domain architecture. HECTD1 contains putative protein-protein interaction domains including two 
armadillo-repeat containing domains (ARM1, residues 8-254; ARM2 residues 892-925 in purple; PDB 4DB8 
[69]), four ankyrin-repeats (residues 395-612 in shades of pink; PDB 4O60 [56]), a SAD1/UNC domain 
(SUN, residues 1115-1244 in yellow; PDB 3UNP [70]), a mind bomb domain (MIB, residues 1266–1338 in 
red; PDB 2DK3), a helix-bundle domain (H, residues 1896–1968 in magenta; PDB 2KZS [71]) and a 
HECT domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]). Domain boundaries are denoted 
according to UniProt and InterPro. Structures were visualized using PyMol.
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that HECTD1 expression is essential for the proper development and survival of 
fetuses in utero. HECTD1 also plays a role in proper neural tube closure. Anencephaly 
occurs when the neural tube does not close properly, which has been linked to 
HECTD1 control of heat shock protein 90 (Hsp90) levels [79]. When Hsp90 secretion 
levels are not properly regulated by HECTD1 ubiquitylation, abnormal neural tube 
development can occur. The continued examination of this important enzyme will 
hopefully clarify the molecular basis for HECTD1’s role in neurodevelopment.
2.4  HECTD4, a genetically linked precursor to cancer and cardiovascular 
disease
HECT domain containing E3 ubiquitin protein ligase 4 (HECTD4; 3996 residues) 
was recently discovered in 2014. A pleiotropic gene screen showed that there were 
links between metabolic syndromes and inflammation, specifically with single nucle-
otide polymorphisms (SNPs) in the HECTD4 gene [80]. Since 2014, HECTD4 has 
also been found to be associated with diabetes, hypertension and cardiovascular dis-
ease, lung adenocarcinoma, urothelial carcinoma and ovarian endometriosis [81–84].
Being one of the larger enzymes within the “other” HECT E3 ubiquitin ligase 
subfamily, it is intriguing that there have been no putative domains annotated for 
HECTD4 except the C-terminal HECT domain (residues 3627–3996). There are 
likely different domains located in the N-terminal region of the HECTD4 protein 
that need to be identified and functionally examined.
Genetic screening has identified various mutations in HECTD4 in cancer cells. 
For example, HECTD4 was recently identified as one of nine genes that correlated 
with the onset of lung adenocarcinoma [83]. Tumor genetic screens have revealed 
in patients with urothelial carcinoma in the bladder (UCB) that mutations in 
HECTD4, Fibrillin-3 Precursor (FBN3) and Citron Rho-Interacting Kinase (CIT) 
were correlated to UCB disease progression [81]. HECTD4 may also be linked to the 
development of ovarian endometriosis (OEM) [82]. However, future studies are 
still needed to verify this relationship.
Already having various genetic links to cancers and cardiovascular disease, 
HECTD4 deserves more attention by the research community to further clarify 
its biological and functional roles in the cell. Currently very little is known about 
HECTD4, therefore it will be imperative to first identify potential similarities in 
protein sequence and/or domain architecture. To better clarify HECTD4’s role in 
ubiquitin biology, it will also be important to discover HECTD4 substrates and 
annotate the sites of HECTD4-dependent ubiquitylation to answer how this myste-
rious HECT E3 ubiquitin ligase contributes to disease development.
2.5  G2E3, a unique multifunctional HECT E3 ubiquitin ligase with RING-like 
features
G2/M-phase specific E3 ubiquitin protein ligase (G2E3; 706 residues) was first 
identified in 2006 and named for its role during the G2/M phase of cell division 
and for having a conserved C-terminal HECT domain [85]. Knockout studies of 
G2E3 in mice demonstrated that this enzyme is essential in preventing apoptotic 
cell death during early embryonic development [86]. Expression levels in G2E3 were 
also observed to increase during early embryogenesis, specifically during central 
nervous system development. This enzyme is also implicated in cell cycle progres-
sion and DNA damage response [85, 87, 88].
G2E3 contains three plant homeodomain (PHD)-type zinc finger repeats, a 
domain typically known to bind to modified histones and act as epigenetic readers 
[89], making it the only known HECT E3 ubiquitin ligase to possess “RING”-like 
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characteristics (Figure 4). G2E3 is primarily found within the nucleus due to its 
N-terminal nucleolar localization signal sequence, while the PHD domains have been 
suggested to cause the translocation of G2E3 to the cytoplasm [85, 86]. Previous 
biochemical studies showed that the ubiquitin ligase activity of G2E3 was exclusively 
found in two of the putative N-terminal PHD domains while the C-terminal HECT 
domain of G2E3 had apparently lost its ubiquitylation activity [86]. Since the PHD 
domains of G2E3 appear to be capable of recruiting E2 enzymes to build K48-linked 
polyubiquitin chains [86], this suggests that the HECT domain of G2E3 may have 
become vestigial through evolutionary pressure. Intriguingly, G2E3 has aspects 
of the RING and HECT E3 ubiquitin ligase families, analogous to members of the 
RING-between-RING (aka RING-BRcat-Rcat) E3 ubiquitin ligases that includes 
parkin and HOIL-interacting protein (HOIP) of the LUBAC complex [91, 92].
G2E3 was recently identified as a potential drug target to increase the efficacy 
of chemotherapy drugs, specifically with Cisplatin [88]. Since Cisplatin is the most 
common chemotherapy drug, much research has been dedicated to increasing 
Cisplatin’s ability to specifically trigger the DNA damage response in cancer cells 
to initiate apoptosis while limiting its exposure time and prescribed duration for 
patients [93]. Clearly, G2E3 is an important nuclear protein whose mechanism 
is currently unresolved. Further studies are needed to clarify how this divergent 
HECT-domain containing E3 ubiquitin ligase works in the cell.
2.6  TRIP12, the multifunctioning E3 ubiquitin ligase essential for 
embryogenesis and DNA damage repair
Thyroid hormone receptor interactor 12 (TRIP12; 2040 residues), was first iden-
tified in 2001 for containing a unique tryptophan-tryptophan-glutamate (WWE) 
domain that is predicted to be involved in ubiquitylation and ADP-ribosylation [94] 
(Figure 5). It also contains two N-terminal ARM domains, similar to HECTD1, and 
Figure 4. 
Domain architecture of G2E3. G2E3 contains three putative plant homeodomain (PHD)-type domains 
(residues 78-128) and a unique HECT-like domain (371-678) as annotated on UniProt and InterPro. 
Representative crystal structures of a PHD domain (human PHD finger protein 13 in cyan with 
Zn-coordinating residues in yellow; PDB 3O70 [90]), which is suggested to interact with DNA and/or proteins 
in the nucleus, while the G2E3 HECT domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]) may 
have lost its ability to catalyze the transfer of ubiquitin. Structures were visualized using PyMol.
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a conserved HECT domain at its C-terminus. TRIP12 is a novel HECT E3 ubiquitin 
ligase that has been shown to take part in various cellular pathways and processes 
including embryogenesis, DNA damage response and the neddylation pathway 
[95–97]. It has been reported that TRIP12 preferentially builds mono- as well as 
K48 and K63 polyubiquitin chains to tag its substrates for degradation and for DNA 
damage site recruitment, respectively [96].
TRIP12 has been shown to be directly and/or indirectly involved in cancer pro-
gression. For example, TRIP12 may serve as an oncogenic drug target for patients 
with acute myeloid leukemia (AML) by blocking a TRIP12 alternative splicing 
event, specifically excising exon3 from the mature TRIP12 mRNA [98]. TRIP12 
also targets pancreas transcription factor 1a (PTF1a) for proteasomal degradation, 
a protein essential for pancreatic cancer development [99]. TRIP12 forms a ternary 
complex with deubiquitylase ubiquitin-specific protease 7 (USP7) that aids in 
hepatocellular carcinoma (HCC) proliferation; when USP7 expression levels are 
heightened, TRIP12 cannot tag ARF tumor suppressor (p14ARF) for ubiquitylation 
[100]. Furthermore, TRIP12 is associated with human papillomavirus (HPV)-
positive head and neck squamous cell carcinoma (HNSCC) due to its mediation of 
p16-related radiation efficacy [101].
Members of the HECT E3 ubiquitin ligase family play important roles in neu-
rodevelopment and their malfunction may be causative in different neurological 
diseases and disorders (reviewed in [4]). Recent genetic screens have been looking 
to identify genetic markers for autism spectrum disorder (ASD) and intellectual 
disability (ID). Interestingly, a de novo mutation in TRIP12 was found in patients 
with or without ASD and displaying characteristics of ID [102]. Further studies to 
clarify the specific mechanism(s) for how mutations in the TRIP12 gene contribute 
to ASD and ID phenotypes are needed.
3. Conclusion
Although much research has and continues to be performed for E6AP and 
members of the NEDD4 family, greater attention on the mysterious “other” HECT 
Figure 5. 
TRIP12 domain architecture. TRIP12 contains two putative armadillo-repeat containing domains (ARM1, 
residues 437-713; ARM2, residues 826-938), a tryptophan-tryptophan-glutamate (WWE)-domain (residues 
749-836) and a conserved HECT domain (1885-1992) as annotated on UniProt and InterPro. Representative 
crystal structures of an ARM domain (in purple; PDB 4DB8 [69]) and WWE domain (in orange; PDB 
6MIW), both of which are suggested to be involved in protein-protein and substrate interactions, as well as 
a HECT domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]) required for ubiquitylation 
activity. Structures were visualized using PyMol.
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E3 ubiquitin ligases is warranted due to their emerging involvement in various 
diseases and neurological disorders. Combining genetic, cell biology, biochemi-
cal, and biophysical approaches to study these unique HECT E3 ubiquitin ligases 
will help to decipher their specific roles and/or functions in the cell as well as 
potentially aid in novel therapy development to treat rare conditions caused by 
the dysfunction of these lesser known members of the HECT E3 ubiquitin ligase 
family.
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AIS acute ischemic stroke
AML acute myeloid leukemia
ANK ankyrin repeat
AREL1 apoptosis resistant E3 ubiquitin protein ligase 1
ARM armadillo-repeat domain
ARTS septin 4
ASD autism spectrum disorder
β2AR adrenergic receptor β2AR
cIAP1/2 cellular inhibitor of apoptosis protein 1/2
circHECTD1 circular RNA HECTD1
CIT citron rho-interacting kinase
EndMT endothelial-mesenchymal transition
FBN3 fibrillin-3 precursor
G2E3 G2/M-phase specific E3 ubiquitin protein ligase
H helix-bundle domain
HACE1 HECT domain and ankyrin repeat containing E3 ubiquitin protein 
ligase 1
HCC hepatocellular carcinoma
HECT hmologous to E6AP C-terminus
HECTD1 HECT domain containing E3 ubiquitin protein ligase 1
HECTD4 HECT domain containing E3 ubiquitin protein ligase 4
HERC HECT and RLD domain-containing
HNSCC head and neck squamous cell carcinoma
HOIP HOIL-interacting protein
HPV human papillomavirus
Hsp90 heat shock protein 90
HtrA2 HtrA serine peptidase 2
ID intellectual disability
IGF immunoglobulin-like fold
MIB mind bomb domain
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p14ARF ARF tumor suppressor
PHD plant homeodomain-type zinc finger
PTF1a pancreas transcription factor 1a
RAR-β retinoic acid receptor beta
RING really interesting new gene
TNFR2 tumor necrosis factor receptor-2
SNPs single nucleotide polymorphisms
SPPRS spastic paraplegia and psychomotor retardation with or without 
seizures
SUN Smad4 activation SAD1/UNC domain
TRIP12 thyroid hormone receptor interactor 12
UCB urothelial carcinoma in the bladder
USP7 deubiquitylase ubiquitin-specific protease 7
WWE tryptophan-tryptophan-glutamate domain
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